Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Wandercraft wins FDA clearance for self-balancing exoskeleton

12 August 2026 · By · Wire by Fusion42

Published

12 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at massdevice.com →

◆ Verified

Fusion42 · 12 August 2026 · Fusion42 review

Wandercraft secured FDA clearance for Eve, a personal self-balancing exoskeleton aimed at adults with spinal cord injuries to support hands-free upright mobility. The company plans a US commercial launch with distribution partnerships and anticipates Medicare reimbursement eligibility within 90 days.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

FDA clearance unlocks US market entry and Medicare funding for Wandercraft's unique self-balancing exoskeleton. If you build mobility devices, new partnerships and reimbursement routes open immediate sales and scaling pathways.

◆ Coverage

1 source · 12 Aug 2026

◆ Related on Wire

◆ Topics

Medtechfda-clearanceexoskeletonspinal-cord-injurymedical-deviceus-launch